Search

Displaying results 6731 - 6740 of 9322 in total
  1. Drug

    Eritoran

    go.drugbank.com/drugs/DB04933
    Investigational

    Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

  2. Drug

    BMS-817399

    go.drugbank.com/drugs/DB14941
    Investigational

    BMS-817399 is under investigation in clinical trial NCT01404585 (Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis).

  3. Drug

    Lapretolimod

    go.drugbank.com/drugs/DB20120
    Investigational

    The usage of the INN stem '-tolimod' in the name indicates that Lapretolimod is a toll-like receptor (TLR) agonist.

  4. Drug

    Upacicalcet

    go.drugbank.com/drugs/DB20023
    Investigational

    The usage of the INN stem '-calcet/-calcet-' in the name indicates that Upacicalcet is a calcium-sensing receptor (CaSR) agonist.

  5. Drug

    Atuveciclib

    go.drugbank.com/drugs/DB20084
    Investigational

    The usage of the INN stem '-ciclib' in the name indicates that Atuveciclib is a cyclin dependant kinase inhibitor.

  6. Drug

    Bavtavirine

    go.drugbank.com/drugs/DB21527
    Investigational

    The usage of the INN stem '-virine' in the name indicates that Bavtavirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI).

  7. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is also being developed for the treatment of Alzheimer disease. … AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.

  8. Drug

    Vinblastine

    go.drugbank.com/drugs/DB00570
    ApprovedInvestigational

    Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

  9. Drug

    Velafermin

    go.drugbank.com/drugs/DB06493
    Investigational

    Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the regeneration and repair of the cells lining the gastrointestinal tract.

  10. Drug

    Urelumab

    go.drugbank.com/drugs/DB12077
    Investigational

    The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with … Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma.